We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BESPONSA (Pfizer Pty Ltd)
Product name
BESPONSA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
195 working days (255)
Active ingredients
inotuzumab ozogamicin (rch)
Registration type
NCE/NBE
Indication
BESPONSA (powder of injection) is indicated for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.